Clinical Commissioning Policy: Eculizumab in the treatment of recurrence of C3 glomerulopathy post-kidney transplant (all ages)

Reference: NHS England: 16054/P
<table>
<thead>
<tr>
<th>Directorate</th>
<th>Operations and Information Trans. &amp; Corp. Ops.</th>
<th>Specialised Commissioning Commissioning Strategy</th>
</tr>
</thead>
</table>

**Publications Gateway Reference:** 05527s

<table>
<thead>
<tr>
<th>Document Purpose</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Name</td>
<td>Eculizumab for the treatment of recurrence of C3 glomerulopathy post-kidney transplant (all ages)</td>
</tr>
<tr>
<td>Author</td>
<td>Specialised Commissioning Team</td>
</tr>
<tr>
<td>Publication Date</td>
<td>22 February 2017</td>
</tr>
<tr>
<td>Target Audience</td>
<td>CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs, Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs</td>
</tr>
</tbody>
</table>

**Additional Circulation List**

<table>
<thead>
<tr>
<th>Description</th>
<th>Routinely Commissioned - NHS England will routinely commission this specialised treatment in accordance with the criteria described in this policy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross Reference</td>
<td>N/A</td>
</tr>
<tr>
<td>Superseded Docs (if applicable)</td>
<td>N/A</td>
</tr>
<tr>
<td>Action Required</td>
<td>N/A</td>
</tr>
<tr>
<td>Timing / Deadlines (if applicable)</td>
<td>N/A</td>
</tr>
<tr>
<td>Contact Details for further information</td>
<td><a href="mailto:england.specialisedcommissioning@nhs.net">england.specialisedcommissioning@nhs.net</a></td>
</tr>
</tbody>
</table>

**Document Status**

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.
Clinical Commissioning Policy: Eculizumab in the treatment of recurrence of C3 glomerulopathy post-kidney transplant (all ages)

First published: February 2017

Prepared by NHS England Specialised Services Clinical Reference Group for Renal Services

Published by NHS England, in electronic format only.
# Contents

1. Introduction .................................................................................................................. 7  
2. Definitions ................................................................................................................... 7  
3. Aims and Objectives .................................................................................................... 8  
4. Epidemiology and Needs Assessment ......................................................................... 8  
5. Evidence Base ............................................................................................................. 10  
6. Criteria for Commissioning ......................................................................................... 14  
7. Patient Pathway ........................................................................................................... 16  
8. Governance Arrangements ......................................................................................... 18  
9. Mechanism for Funding ............................................................................................. 18  
10. Audit requirements .................................................................................................... 18  
11. Documents which have informed this Policy ............................................................. 19  
12. Date of Review .......................................................................................................... 19  
13. References .................................................................................................................. 20
Policy Statement
NHS England will routinely commission treatment of recurrent C3 disease post kidney transplant with eculizumab in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources. This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement
Promoting equality and addressing health inequalities are at the heart of NHS England’s values. Throughout the development of the policies and processes cited in this document, we have:

- Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities

Plain Language Summary
About C3 glomerulopathy
‘Glomerulonephritis’ is a kidney problem where there is inflammation in the kidney. C3 glomerulopathy is one type of glomerulonephritis. In C3 glomerulopathy there are problems with the regulation of a part of the immune system (‘complement system’). This results in the build-up of the protein ‘C3’ in the kidneys. C3 glomerulopathy includes C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).

Each year there are 1 to 2 people per million of the UK population who have C3 glomerulopathy. The outlook for the kidneys of these people (‘renal prognosis’) is poor.
- There is a 30% risk of kidney failure (‘end stage renal disease’) after two years.
• In most people, the risk of the illness coming back in the transplanted kidney is over 70% and there is a more than a 50% chance the kidney will be lost.

About the current treatment
The most effective treatment for people with C3 glomerulopathy who have had a kidney transplant is not clear. This is because existing treatments have not been tested in robust clinical trials. This is most likely because of the small numbers of people with the illness – where it is difficult to find enough people to do randomised controlled trials (RCTs).

About the new treatment
This treatment is the medicine ‘eculizumab’ which is within a group of medicines called “monoclonal antibodies”.

What we have decided
NHS England has carefully reviewed the evidence to treat C3 disease post kidney transplant with eculizumab. We have concluded that there is enough evidence to make the treatment available.
1 Introduction

This document describes the evidence that has been considered by NHS England in formulating a policy to routinely commission eculizumab for the treatment of recurrence of C3 glomerulopathy following a kidney transplant. Eculizumab is a recombinant humanised monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a (a proinflammatory anaphylatoxin) and C5b and preventing the generation of the terminal complement complex C5b-9 (membrane attack complex), which causes cell lysis and death in pathogens.

Eculizumab has a marketing authorisation in the UK for treating adults and children with atypical haemolytic uraemic syndrome (aHUS) or paroxysmal nocturnal haemoglobinuria (PNH) (summary of product characteristics for Soliris).

Like C3 glomerulopathy, aHUS and PNH are complement-mediated diseases, which stimulated interest in using eculizumab to treat this condition. Use of eculizumab to treat people with C3 glomerulopathy, or to treat recurrence of the condition in a transplanted kidney, is outside the approved indications.

2 Definitions

C3 glomerulopathy (C3G) is a renal disease due to abnormal control of complement activation, deposition, or degradation and characterized histologically by predominant glomerular complement C3 deposition and electron-dense deposits (Pickering et al, 2013). It is identified on renal biopsy by the finding of complement C3 that is at least two orders of magnitude more intense than any other immune reactant (Hou et al, 2014). C3G includes the sub-types dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).
3 Aims and Objectives

This policy considered treatment with eculizumab for those patients (both adults and children) with C3 glomerulopathy who experience recurrent disease post renal transplant.

The objectives were to consider where there is the risk of the rapid (within months) loss of a transplanted kidney to highly aggressive recurrent disease.

4 Epidemiology and Needs Assessment

C3G is a rare disease with an estimated prevalence of 1-2 cases per million in the UK (Medjeral-Thomas et al, 2014). The clinical course of C3G is derived from cohort studies, which include individuals with C3GN, DDD or both. Due to its rarity, cohort studies are necessarily of low patient number and controlled trials are lacking. The sub-types of C3G together with its variable clinical course result in considerable disease heterogeneity. The condition has a poor prognosis with 10 year renal survival of approximately 50% in most cases. The following summarises key points from some of the major cohort publications.

In a series of patients from France with C3G (including n=29 with DDD and n=56 with C3GN), the 10-year renal survival was 63.5% (Servais et al, 2012). Cumulative renal survival was worse in adult patients with DDD; worse if glomerular filtration rate (GFR) at diagnosis was <60mls/min per 1.73m2 but was not related to circulating complement C3 levels. Renal survival was greater with the use of either angiotensin-converting enzyme inhibition or receptor blockade but not with the use of immunosuppression. Recurrence rate in renal transplantation was 54.5% (n=6) for the DDD sub-group and 60% (n=6) for the C3GN sub-group.

In a series of patients from the UK and Ireland with C3G (including n=21 with DDD and n=59 with C3GN), age > 16 years, DDD subtype, and crescentic GN, but not low circulating C3 levels, were independent predictors of end-stage renal disease (ESRD) (Medjeral-Thomas et al, 2014). Of the n=20 reaching ESRD, n=6 with DDD and n=7 with C3GN underwent renal transplantation. DDD recurred in all patients
and contributed to graft loss in n=3. Recurrence occurred in n=4 of the C3GN patients who were transplanted and contributed to graft loss in n=3.

In a series of patients with DDD (n=32) from North America (Nasr et al, 2009) clinical follow up data were available for both children (n=13, mean follow up duration 79.4 months, range 2-288) and adults (n=14, mean follow up duration 48.5 months, range 4-156). End-stage renal failure (ESRF) was more common in adults (n=6, 42.9%) compared to children (n=1, 7.7%). By univariate analysis correlates of ESRF included older age and higher creatinine at biopsy but not circulating C3 levels. Combined treatment with immunosuppression and renin angiotensin system blockade was associated with better renal survival than either treatment modality alone. Notable patients who received immunosuppression therapy had higher percentage of crescents on renal biopsy. In an earlier study of DDD (n=27 patients), the presence of either crescents or glomerular neutrophils in the initial biopsy correlated with progressive disease (Bennett et al, Am J Kid Dis 1989).

In a series of paediatric patients from North America (n=75) assessing recurrence of DDD in renal transplant, the 5 year renal survival was approximately 50% (Braun et al, 2005). The presence of crescents in renal transplant biopsies was associated with worse graft survival. There was no correlation between circulating C3 levels and disease recurrence (with or without graft failure) a finding that had been previously reported (Leibowitch et al, 1979).

In a series of adult patients from the Netherlands (n=11) with DDD and first renal transplant, all transplant biopsies performed due to raised serum creatinine showed recurrent DDD (Andresdottir et al, 1999). In n=3 graft loss occurred as sole consequence of disease recurrence and in these cases renal biopsy showed both crescents and neutrophils.

In CFHR5 nephropathy, a genetically characterized familial C3GN, renal failure is more common in male patients (Athanasiou et al, 2011). In an assessment of n=82 cases, 18 individuals (20%) reached ESRD with a striking male preponderance (n=14 males and n=4 females). Ten of the 18 individuals with ESRD received 11 renal transplants: n=2 were deceased whilst n=8 had functioning grafts at the time of
reporting (graft times 1-23 years). The development of proteinuria appears to be a poor prognostic sign, particularly in male patients, and decline in renal function is associated with fever-associated macroscopic haematuria.

5 Evidence Base

NHS England has concluded that there is sufficient evidence to support a policy for the routine commissioning of eculizumab for the treatment of recurrence of C3 glomerulopathy following a kidney transplant.

Refractory C3G refers to declining renal function that is unresponsive to typical immunosuppressive modalities utilised to treat glomerulonephritis. In patients with rapidly deteriorating renal function plasma exchange has been utilised. None of these approaches alone, or in combination, have proven to be widely effective in the treatment of C3G. Consequently many patients with C3G develop refractory disease in either the native or transplant kidney.

There is no definitive therapy for C3G but as it is a complement-associated disease, case reports of the use of eculizumab in refractory disease can be found in the literature and were considered.

The prevention of C5 activation would be expected to stop the C5-mediated but not C3-mediated damage in C3G. Activation of C5 results in production of the pro-inflammatory molecule C5a and initiates complement terminal pathway activation. The therapeutic benefit of C5 inhibition is most likely to seen in situations where there is glomerular inflammation (e.g. crescents, endocapillary hypercellularity, neutrophil accumulation) together with evidence of glomerular C5 activation (readily detected by the presence of the terminal complement component C9). There is pre-clinical data to support this assertion using an experimental model of C3G (Pickering et al PNAS, 2006).

Case reports and series of the use of eculizumab in C3G include its use in de novo disease and in recurrent disease in the renal transplant. These are all Scottish Intercollegiate Guideline Network (SIGN) levels of evidence grade 3 (non-analytical
studies). Table 1 summarises the reported literature. These reports were identified by literature searches. Searches were performed using PubMed (www.ncbi.nlm.nih.gov) and conducted independently to inform the policy. Search terms used were: eculizumab, C3 glomerulopathy, Dense Deposit Disease. The search was limited to reports published in the English language. With the exception of one open label uncontrolled trial, these consist of case reports. There is no controlled clinical trial data on the use of eculizumab in C3G and it is not licensed for the treatment of C3G.

The recommendations are derived from evidence defined as SIGN level Grade D.

From the published data, a therapeutic response to eculizumab in both native and allograft refractory disease is most often reported when there is evidence of glomerular inflammation, particularly crescentic disease with renal impairment.

Table 1

<table>
<thead>
<tr>
<th>Evidence Type/SIGN grade/Reference</th>
<th>Diagnosis (age/sex)</th>
<th>Indication</th>
<th>Treatment duration (months)</th>
<th>Clinical Response</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case report SIGN grade 3 Daina et al 2012</td>
<td>DDD (22F)</td>
<td>Creatinine rise and proteinuria</td>
<td>11</td>
<td>Yes</td>
<td>Proteinuria fell to non-nephrotic range</td>
</tr>
<tr>
<td>Case report SIGN grade 3 Vivarelli et al 2012</td>
<td>DDD (17/M)</td>
<td>Proteinuria</td>
<td>18 + 9</td>
<td>Yes</td>
<td>Glomerular sclerosis and tubular atrophy developed despite reduction in glomerular C5b-9 Reduction in proteinuria Rise in proteinuria on treatment cessation which improved on treatment recommencement</td>
</tr>
<tr>
<td>Case report SIGN grade 3 McCaughan et al 2012</td>
<td>DDD in renal allograft (29F)</td>
<td>Creatinine rise and proteinuria</td>
<td>2.5</td>
<td>Yes</td>
<td>Crescentic DDD</td>
</tr>
<tr>
<td>Open labelled non-controlled case series</td>
<td>DDD (22M)</td>
<td>Creatinine rise</td>
<td>12</td>
<td>Yes</td>
<td>rise in serum creatinine rise on treatment cessation</td>
</tr>
<tr>
<td></td>
<td>DDD</td>
<td>Creatinine</td>
<td>9</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Case report</td>
<td>SIGN grade 3</td>
<td>(42M) DDD in renal allograft (32M)</td>
<td>Creatinine rise and proteinuria</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>----------------------------------</td>
<td>---------------------------------</td>
<td>----</td>
<td>-----</td>
</tr>
<tr>
<td>SIGN grade 3 Bomback et al 2012</td>
<td>C3GN (25M)</td>
<td>Creatinine rise and proteinuria</td>
<td>12</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>SIGN grade 3 Bomback et al 2012</td>
<td>C3GN in renal allograft (22M)</td>
<td>Creatinine rise and proteinuria</td>
<td>12</td>
<td>No</td>
<td>Patient developed a post-trial period rise in creatinine associated with crescentic C3GN improved on combination of plasma exchange, pulse steroids and re-commencement of eculizumab</td>
</tr>
<tr>
<td>C3GN in renal allograft (20M)</td>
<td>Creatinine rise</td>
<td>12</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Case report</td>
<td>C3GN in renal allograft (21M)</td>
<td>Creatinine rise and proteinuria</td>
<td>12</td>
<td>Partial response</td>
<td>Primary renal diagnosis of DDD Allograft biopsy 6 and 12 month post-treatment initiation showed disease progression</td>
</tr>
<tr>
<td>Case report</td>
<td>C3GN (16F)</td>
<td>Proteinuria</td>
<td>10</td>
<td>No</td>
<td>C3GN with membranoproliferative changes</td>
</tr>
<tr>
<td>Case report</td>
<td>C3GN (16M)</td>
<td>Proteinuria</td>
<td>3.5</td>
<td>Yes</td>
<td>Reduction in proteinuria</td>
</tr>
<tr>
<td>Case report</td>
<td>DDD (8F)</td>
<td>Creatinine rise and proteinuria</td>
<td>6</td>
<td>Yes</td>
<td>Crescentic DDD with positive glomerular C5b-9 Normalisation of both creatinine and proteinuria</td>
</tr>
<tr>
<td>Case report</td>
<td>DDD</td>
<td>Proteinuria</td>
<td>8</td>
<td>Yes</td>
<td>Crescentic DDD</td>
</tr>
<tr>
<td>SIGN grade 3</td>
<td>Ozkaya et al 2014</td>
<td>(14F)</td>
<td>Proteinuria</td>
<td>Normalisation of proteinuria</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------------</td>
<td>-------</td>
<td>--------------</td>
<td>----------------------------</td>
<td></td>
</tr>
<tr>
<td>Case report</td>
<td>SIGN grade 3</td>
<td>DDD</td>
<td>4</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>SIGN grade 3</td>
<td>Berthe-Aucejo et al 2014</td>
<td>(17M)</td>
<td>Proteinuria</td>
<td>Normalisation of proteinuria</td>
<td></td>
</tr>
<tr>
<td>Case report</td>
<td>SIGN grade 3</td>
<td>DDD in renal allograft (14f)</td>
<td>30</td>
<td>Yes</td>
<td>No histological progression on renal biopsy 6 months after treatment onset</td>
</tr>
<tr>
<td>Case series</td>
<td>SIGN grade 3</td>
<td>C3G (27F)</td>
<td>Creatinine rise and proteinuria</td>
<td>ongoing</td>
<td>Yes</td>
</tr>
<tr>
<td>SIGN grade 3</td>
<td>Le Quintec et al 2015</td>
<td>C3G in renal allograft (63F)</td>
<td>Creatinine rise</td>
<td>ongoing</td>
<td>Yes</td>
</tr>
<tr>
<td>Case report</td>
<td>C3G (45M)</td>
<td>Creatinine rise and proteinuria</td>
<td>ongoing</td>
<td>Yes</td>
<td>Partial reduction in proteinuria</td>
</tr>
<tr>
<td>Case report</td>
<td>SIGN grade 3</td>
<td>C3GN (5M)</td>
<td>Proteinuria</td>
<td>19</td>
<td>Yes</td>
</tr>
<tr>
<td>Case report</td>
<td>SIGN grade 3</td>
<td>C3GN (15F)</td>
<td>Proteinuria</td>
<td>10</td>
<td>Yes</td>
</tr>
<tr>
<td>2015</td>
<td>Case report</td>
<td>C3GN (38F)</td>
<td>Dialysis-dependent</td>
<td>ongoing</td>
<td>Yes</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>------------</td>
<td>--------------------</td>
<td>--------</td>
<td>-----</td>
</tr>
<tr>
<td>SIGN grade 3</td>
<td>Inman et al 2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case series</td>
<td>SIGN grade 3</td>
<td>DDD</td>
<td>Creatinine rise and proteinuria</td>
<td>ongoing in n=4 cases</td>
<td>Yes</td>
</tr>
<tr>
<td>Oosteveld et al 2015</td>
<td>5 cases</td>
<td>(1.9M, 6.4F, 6.9F, 5.8M, 12.9F)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6 Criteria for Commissioning

NHS England will commission eculizumab for the treatment of recurrence of C3 glomerulopathy post-kidney transplant in accordance with the criteria outlined in this document. The aim of this commissioning policy is to prevent the rapid (within months) loss of a transplanted kidney to highly aggressive recurrent disease.

NHS England will not routinely commission eculizumab for the treatment of low grade recurrent disease.

In creating this policy NHS England has reviewed the literature and options for treatment including the NICE Evidence Review “ESUOM44, Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab, June 2015”. It has considered the place of eculizumab in current clinical practice.

This policy document outlines the proposed arrangements for the commissioning and funding of eculizumab for the population in England.
Starting criteria

NHS England will commission eculizumab for the treatment of recurrent disease post-transplant in patients with C3 glomerulopathy only if all the following clinical criteria are met:

a. A primary renal diagnosis of C3 glomerulopathy confirmed by renal biopsy including light microscopy, immunofluorescence and electron microscopy.

b. Recurrent disease characterised on biopsy by an active glomerulonephritis with cellular crescents. Histopathology will be reviewed by a single centre with expertise in the pathology of C3 glomerulopathy.

c. Evidence of glomerular C9 deposition on transplant biopsy.

d. Recurrent disease occurring at any time post-transplant.

e. Evidence at the time of recurrence of a significant decline of transplant function (>20% decline in eGFR) within the previous three months. This criterion will not be necessary if the recurrence occurs immediately after transplantation when transplant function has not yet been established.

f. No other cause for the decline in transplant function can be identified.

Figures provided by NHSBT show that in the past ten years 39 patients with DDD have been transplanted. In the same period, three patients with DDD have lost their transplant to recurrent disease. There are a total of 59 patients in the UK with a functioning kidney transplant whose primary renal disease is said to be DDD and there are currently six patients on the active transplant waiting list. From the available published information, we estimate that 70% of patients will develop recurrent disease at some stage and that a maximum of 50% of patients with recurrent disease will meet the above criteria. Whilst the information available from NHSBT may be subject to underreporting it is estimated that fewer than five patients per year will meet all the above criteria.

If all the criteria are met, eculizumab should be started using the same dose as recommended for the treatment of atypical haemolytic uraemic syndrome (at www.rarerenal.org).
Stopping criteria

Treatment should be continued for four months. The possible outcomes at or before this time are:

2. Ongoing deterioration in graft function (eGFR) with no evidence of a response to treatment.
3. Stabilisation of graft function (eGFR).
4. An improvement in graft function (eGFR).

For 1 and 2, eculizumab should be withdrawn and not reintroduced. For 3 and 4, eculizumab should also be withdrawn after four months of treatment but could be reintroduced for a further four month period followed by further review if there is a subsequent deterioration in graft function (of a similar magnitude to that defined in criterion e) of the starting criteria), which on biopsy is shown to be due to active recurrent disease. Again, there should be no other identifiable cause for the decline in transplant function.

7 Patient Pathway

It is proposed that decisions about the commencement, monitoring and stopping of treatment will be made in conjunction with the national named expert reference centre MDT. Ongoing care should continue to be provided locally but with co-ordination through the virtual MDT to reach a decision with the national named expert centre.
Patient with DDD / C3GN

Kidney Transplant

Diagnosis of C3 Glomerulopathy confirmed by renal biopsy including electron microscopy and immunofluorescence

Recurrence
Primary diagnosis of C3GN
Active glomerulonephritis & cellular crescents
Glomerular C9 deposition
>20% decline in eGFR within previous 3 months

All Starting criteria met - treat with eculizumab for 4 months

Review at 4 months

Response 1:
Loss of Transplant
OR
Ongoing deterioration / no response

Withdraw Treatment
Do Not reintroduce

Response 2:
Stabilisation of graft function
OR Improvement of graft function

Treat for 4 months and monitor response
- if all criteria met reintroduce for further 4 months

Histopathology confirming a recurrence to be reviewed by national centre with expertise in the pathology of C3 glomerulopathy

Virtual MDT in named centre to review case

Diagnosis of C3 Glomerulopathy confirmed by renal biopsy including electron microscopy and immunofluorescence
9 Governance Arrangements

Access to treatment will be decided at a national MDT supported by a national named expert centre but will be delivered locally to patients.

Potential cases require a multidisciplinary assessment via a ‘virtual MDT’ with the named expert reference centre. Histopathology confirming a diagnosis of recurrence is required and would be reviewed by a single centre with expertise in the pathology of C3 glomerulopathy. Clinicians will be required to provide all relevant information.

The Highly Specialised Services Team and Renal CRG Chair should be informed of each case.

Due to the uncertainty about the evidence base the policy will be in force for 3 years from publication to support data collection and review of efficacy, unless superseded by other NHS England policy.

10 Mechanism for Funding

NHS England will be responsible for commissioning eculizumab in line with this policy on behalf of the population of England. The drug will be funded through local specialised commissioning teams.

11 Audit requirements

A register of all cases to include clinical details and outcomes will be developed and held by the expert centre. Clinicians will be required to record both short and long term outcomes of individuals with recurrent C3 glomerulopathy post-kidney transplant treated with eculizumab.

The dataset will be agreed by NHS England and will be mandatory for providers to complete.
12 Documents which have informed this Policy

National Institute for Health and Care Excellence Evidence Summary ESUOM44

13 Date of Review

This document will be reviewed when information is received which indicates that the policy requires revision.
References


